Richard L. Lindstrom, MD
Richard L. Lindstrom, MD's purchase track record
Richard L. Lindstrom, MD has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/20/2026 | OCUL | $461K | +5.8% | +42.3% | +11.1% |
| 5/8/2025 | OCUL | $70K | +65.1% | +42.7% | +18.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Lucid Capital Markets Begins Coverage of LENSAR, Sets $11 Target. Lucid Capital Markets has started coverage on LENSAR and issued a positive rating. The firm set a price target of $11, which sits near the upper end of the company’s 52‑week range. The new outlook may attract attention from investors looking at LENSAR’s valuation relative to its peers. The coverage adds a fresh perspective to the market’s view of the stock.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Harrow (HROW) gains analyst support and conference buzz amid turnaround focus. Recent coverage highlights growing attention on Harrow’s ophthalmic pipeline, with analysts maintaining a $63 price target and an average target of $65. A recent conference has generated buzz, while options activity suggests market participants are watching the stock closely. The company’s Q3 results are expected to confirm whether the turnaround plan is taking hold.
Transaction History
| OCUL | ▲ Buy | Grant | 14,000 | $0 | 6/10/2026 | View on chart |
| LNSR | ▲ Buy | Grant | 17,421 | $0 | 6/3/2026 | View on chart |
| OCUL | ▲ Buy | Open Market | 60,229 | $461K | 2/20/2026 | View on chart |
| OCUL | ▲ Buy | Grant | 14,000 | $0 | 6/11/2025 | View on chart |
| LNSR | ▲ Buy | Grant | 7,374 | $0 | 5/23/2025 | View on chart |
| OCUL | ▲ Buy | Open Market | 10,000 | $70K | 5/8/2025 | View on chart |
| OCUL | ▲ Buy | Grant | 12,000 | $0 | 7/24/2024 | View on chart |
| LNSR | ▲ Buy | Grant | 22,000 | $0 | 5/7/2024 | View on chart |
| OCUL | ▲ Buy | Option Exercise | 18,939 | $167K | 2/27/2024 | View on chart |
| OCUL | ▲ Buy | Option Exercise | 11,363 | $100K | 2/27/2024 | View on chart |
| OCUL | ▲ Buy | Grant | 12,000 | $0 | 6/14/2023 | View on chart |
| LNSR | ▲ Buy | Grant | 9,288 | $0 | 5/25/2023 | View on chart |
| HROW | ▼ Sell | Open Market | 40,000 | $505K | 9/30/2022 | View on chart |
| OCUL | ▲ Buy | Grant | 8,933 | $0 | 6/16/2022 | View on chart |
| LNSR | ▲ Buy | Grant | 4,285 | $0 | 5/25/2022 | View on chart |
| OCUL | ▲ Buy | Option Exercise | 9,469 | $12K | 5/12/2022 | View on chart |
| HROW | ▼ Sell | Open Market | 3,900 | $39K | 9/24/2021 | View on chart |
| HROW | ▼ Sell | Open Market | 5,840 | $53K | 9/16/2021 | View on chart |
| HROW | ▼ Sell | Open Market | 14,160 | $129K | 9/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
OCUL: UBS initiates coverage and Nasdaq grant filing reported
UBS has started coverage of Ocular Therapeutix and set a price target of $14. The company also disclosed inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). OCUL presented its latest data at the Euretina 2026 conference, highlighting ongoing development efforts. Analyst commentary this week varies, with some listing the stock among top healthcare picks while others note its unprofitable status.
OCUL: UBS initiates coverage and Nasdaq grant filing reported. UBS has started coverage of Ocular Therapeutix and set a price target of $14. The company also disclosed inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). OCUL presented its latest data at the Euretina 2026 conference, highlighting ongoing development efforts. Analyst commentary this week varies, with some listing the stock among top healthcare picks while others note its unprofitable status.